What Are the Side Effects of FOLFOX Chemotherapy?

FOLFOX chemotherapy, a combination of fluorouracil (5-FU), leucovorin, and oxaliplatin used mainly for colorectal cancer, produces a wide range of side effects that touch nearly every system in the body. The most distinctive is peripheral neuropathy from oxaliplatin, which starts as an odd sensitivity to cold and can develop into lasting nerve damage. But neuropathy is only one piece: blood count drops, nausea, fatigue, heart-related risks, allergic reactions, and subtler effects on the liver, fertility, and cognition all belong to the picture. Understanding which side effects are common versus rare, which ones fade versus persist, and what can be done about them makes a real difference in how you navigate treatment.

The Signature Side Effect: Nerve Damage From Oxaliplatin

If there is one side effect that defines the FOLFOX experience, it is peripheral neuropathy caused by the oxaliplatin component. It shows up in two distinct forms. The first is acute cold-triggered sensitivity that can begin within hours of an infusion. Touching cold objects, drinking cold water, or even breathing cold air can produce tingling, numbness, or a painful tightening sensation in the hands, feet, throat, or jaw. This happens because oxaliplatin alters how sensory nerves respond to temperature: research shows the drug lowers the expression of certain potassium channels while boosting the activity of pro-excitatory channels, essentially making nerve cells fire too easily when they encounter cold.¹ Most people on FOLFOX learn quickly to avoid cold drinks and wear gloves when opening the refrigerator during the first few days after each cycle.

The second form is chronic neuropathy, a cumulative problem that builds with each infusion. As the total dose of oxaliplatin climbs, numbness and tingling in the fingers and toes can become persistent, interfering with fine motor tasks like buttoning a shirt or sensing the texture of objects underfoot. Severity tends to correlate with how much oxaliplatin you have received overall.

When Neuropathy Lingers After Treatment Ends

One of the most frustrating realities of FOLFOX is that neuropathy does not always resolve once chemotherapy is over. A study following patients long after their last oxaliplatin dose found that roughly 80% still reported residual nerve symptoms, with widespread loss of sensation to pinprick and vibration on clinical testing. Nerve conduction studies confirmed that sensory nerve damage had not recovered, consistent with lasting axonal injury.² A systematic review reached a similar conclusion: neuropathy remains present in a large proportion of patients a year or more after finishing treatment, and higher cumulative doses make long-term problems more likely.³

Five-year follow-up data from one study showed that while no patients still had the most severe grade of neuropathy at the one-year mark, about one in five survivors still had mild or moderate residual symptoms five years out.⁴ The common reassurance that “it all goes away eventually” understates what actually happens for a sizable minority. For some people, the numbness or tingling in the hands and feet becomes a permanent part of daily life after treatment.

Blood Count Drops

FOLFOX suppresses the bone marrow, leading to drops in white blood cells, red blood cells, and platelets. Low neutrophil counts (neutropenia) are the most treatment-disrupting of these, since they raise the risk of serious infection and often force delays between cycles. In one retrospective study, low blood counts were the single most common reason for unplanned treatment delays, affecting about a third of patients and accounting for the majority of schedule disruptions.⁵ Another study found that roughly 90% of patients experienced some form of dose-limiting toxicity during adjuvant FOLFOX, with neutropenia-related problems accounting for most of those.⁶

Thrombocytopenia, a drop in platelets, is usually mild and related to bone marrow suppression. Rarely, oxaliplatin can trigger an immune-mediated form where the body produces antibodies that destroy platelets rapidly. Case reports describe patients whose platelet counts plummeted after later cycles of oxaliplatin, sometimes leading to bleeding complications that required corticosteroid treatment.⁷⁸ This immune-mediated version is uncommon but worth knowing about because it can appear suddenly, even after multiple uneventful cycles.

Nausea, Vomiting, and Other Digestive Problems

Oxaliplatin is classified as moderately emetogenic, meaning it causes nausea and vomiting in a significant number of patients if not managed with preventive medication. Standard antiemetic regimens typically combine a serotonin-blocking drug with a corticosteroid given before each infusion.⁹ For patients at higher risk of nausea, adding a third agent can improve control. A trial of the three-drug combination of aprepitant plus palonosetron plus dexamethasone found that about three-quarters of FOLFOX patients achieved complete control of nausea and vomiting in the first cycle, rising to over 80% by the fourth cycle.¹⁰ A separate study found that adding olanzapine to standard antiemetics improved control of delayed nausea, the queasy feeling that sets in a day or two after treatment.¹¹

Beyond nausea, diarrhea and mouth sores (mucositis) are common gastrointestinal complaints during FOLFOX. Both are driven largely by the 5-FU component, which damages rapidly dividing cells in the gut lining. A review of adjunctive treatments found that probiotics showed effectiveness in preventing and treating chemotherapy-related gastrointestinal damage, and that glutamine supplements helped reduce chemotherapy-induced diarrhea specifically.¹² Many patients also experience loss of appetite, taste changes, and general fatigue that compound the digestive symptoms.

Heart-Related Risks From the 5-FU Component

Cardiotoxicity is one of the less talked-about but potentially serious side effects of FOLFOX, and it comes from the 5-FU component rather than oxaliplatin. The leading explanation is coronary vasospasm, where the blood vessels supplying the heart temporarily constrict, reducing blood flow. Patients can develop chest pain, abnormal heart rhythms, or electrocardiogram changes that mimic a heart attack, even though their coronary arteries look clear on imaging.¹³ The range of possible cardiac effects runs from silent electrical changes picked up only on a monitor all the way to heart muscle damage and heart failure.¹⁴

Chest pain, shortness of breath, or a rapid heartbeat during or shortly after a 5-FU infusion should be reported immediately. People with pre-existing heart disease face a higher risk, but 5-FU cardiotoxicity can also occur in people with no cardiac history. If it happens, the treatment team generally stops 5-FU and considers alternatives, since re-exposure carries a high rate of recurrence.

Allergic Reactions to Oxaliplatin

Hypersensitivity reactions to oxaliplatin are uncommon in the first few cycles but become increasingly likely with repeated exposure. The reactions are mostly driven by the immune system and can involve virtually any organ system: skin flushing, itching, and hives; throat tightness or difficulty breathing; drops in blood pressure; nausea; and in severe cases, full anaphylaxis.¹⁵ These reactions tend to appear after several uneventful cycles, often around cycle 6 or later, which can catch patients off guard just when they have started to feel comfortable with the routine.

When oxaliplatin remains important for a patient’s treatment plan, desensitization protocols can allow them to continue receiving it. These involve giving the drug in very small, gradually increasing amounts under close monitoring, essentially coaxing the immune system into temporary tolerance. One center reported performing 200 desensitizations safely across 48 patients who had already had allergic reactions. Skin testing helped stratify risk, with positive results predicting a higher chance of a reaction during the desensitization itself.¹⁶ Desensitization typically requires an overnight hospital stay with premedication including antihistamines and steroids.¹⁷

Liver Damage and Sinusoidal Obstruction

Oxaliplatin can injure the small blood vessels inside the liver, a condition called sinusoidal obstruction syndrome. This is most often discussed in the context of patients with liver metastases who receive FOLFOX before surgery, because the liver damage can complicate the operation and recovery. The problem involves distinctive dilation of the tiny channels (sinusoids) through which blood flows inside the liver.¹⁸ In milder forms, it may show up only as abnormal liver tests or a slightly enlarged spleen. In more serious cases, it can cause portal hypertension and impair liver function. For patients heading toward liver surgery, oncologists weigh the benefits of additional chemotherapy cycles against the growing risk of liver injury.

Cognitive Changes During and After Treatment

Many chemotherapy patients report feeling mentally foggy during treatment, often described as “chemo brain.” With FOLFOX specifically, the research picture is mixed. A review of studies examining cognitive function after cytotoxic chemotherapy noted that two out of three studies investigating FOLFOX in colorectal cancer patients found no significant changes in cognitive performance after treatment.¹⁹ One longitudinal study specifically found that anxiety, depression, fatigue, and hemoglobin levels did not explain the cognitive test results, suggesting that whatever cognitive effects exist may not simply be a byproduct of feeling exhausted or down.²⁰ A brain-imaging study did identify relationships between chemotherapy cycles and activity patterns in prefrontal brain regions in colorectal cancer patients, hinting that subtle neurological changes occur even when standard cognitive tests come back normal.²¹

The bottom line for patients: if you feel mentally sluggish during FOLFOX, you are not imagining it, but the evidence suggests that for most people the changes are subtle and may not show up on formal testing. This is one area where patient experience and research findings do not always line up neatly.

Fertility and Reproductive Effects

For younger patients, the effect of FOLFOX on fertility is a pressing concern. The available evidence is cautiously reassuring. A study tracking sex hormones and sperm quality in men receiving adjuvant oxaliplatin-based treatment found that while hormone levels shifted during chemotherapy and there was a trend toward lower sperm concentration, these changes reversed after treatment ended. No patients developed permanent loss of sperm production or sustained low testosterone.²²

In women, the picture requires more caution. Oxaliplatin-based chemotherapy has been linked to reduced anti-Müllerian hormone levels, a marker of ovarian reserve, and elevated follicle-stimulating hormone, both signs of diminished fertility potential. One evaluation found that about 16% of female patients developed persistent loss of menstruation after FOLFOX.²³ Chemotherapy overall is considered to carry a low-to-moderate risk of fertility impairment in colorectal cancer patients, but the individual impact depends heavily on age and baseline ovarian reserve. Fertility preservation discussions, including egg or embryo freezing, should ideally happen before treatment begins.

The Role of DPD Deficiency

Not everyone processes 5-FU at the same rate, and this matters enormously for side effects. The enzyme dihydropyrimidine dehydrogenase (DPD) is the main pathway for breaking down fluoropyrimidine drugs. People with reduced DPD activity clear the drug more slowly, allowing toxic levels to build up. DPD deficiency can lead to severe and sometimes fatal toxicity, including dangerous drops in blood counts, severe mucositis, and overwhelming diarrhea.²⁴ Screening for DPD deficiency before starting FOLFOX has become standard practice in several countries. If a deficiency is found, the 5-FU dose is reduced or an alternative drug is chosen.

Managing Neuropathy Through Dose Strategies and Cold Therapy

Because neuropathy is cumulative and potentially permanent, oncologists have developed strategies to limit oxaliplatin exposure without sacrificing effectiveness. The “stop-and-go” approach involves pausing oxaliplatin after a set number of cycles while continuing the 5-FU and leucovorin, then reintroducing oxaliplatin later if needed. A landmark trial comparing continuous FOLFOX to this intermittent strategy found no meaningful difference in survival between the two groups, while patients in the stop-and-go arm experienced less severe neuropathy as treatment progressed.²⁵ A modified version of this approach using oral maintenance therapy similarly found that severe neuropathy was rare when oxaliplatin was paused early.²⁶

A recent meta-analysis examined reduced oxaliplatin exposure across multiple cancer types and found that giving less oxaliplatin cut the rates of moderate and severe neuropathy substantially, with no statistically significant differences in disease-free survival or overall survival in adjuvant colorectal cancer settings.²⁷ This is an increasingly important finding because it suggests patients and oncologists can weigh neuropathy risk more carefully without automatically assuming that less drug means worse cancer outcomes.

Cold therapy during infusions is another emerging prevention strategy. The idea is to cool the hands and feet during oxaliplatin administration, constricting blood flow to the extremities and reducing how much drug reaches the peripheral nerves. A systematic review found that cooling methods were effective in preventing neuropathy in more than half the studies examined, though a few trials did not find a significant benefit, likely reflecting differences in how the cooling was delivered and how long it lasted. Frozen gloves and socks were among the most commonly studied and effective approaches.

How Infusion Schedule Affects Toxicity

The specific way 5-FU is delivered also influences which side effects are most prominent. FOLFOX regimens that use a single bolus dose of 5-FU followed by a continuous infusion tend to cause fewer blood count problems and fewer gastrointestinal side effects compared with older double-bolus schedules. A systematic review comparing different fluoropyrimidine-oxaliplatin combinations found that single-bolus regimens carried a reduced risk of most blood-related toxicities (with the exception of anemia) and also lowered the risk of gastrointestinal problems and peripheral neuropathy relative to double-bolus approaches.²⁸ This is one reason why modified FOLFOX6, which uses a single bolus followed by a 46-hour infusion, has become the most widely used version of the regimen in current practice.